Recent clinical incidents in the United Kingdom highlight significant discrepancies between established medical protocols and patient safety outcomes, specifically regarding medication errors and prescribing irregularities in pediatric care.

英國近期發生的臨床事故凸顯了既定醫療方案與病人安全結果之間的顯著差異，特別是在兒科護理中的用藥錯誤與開藥違規方面。

The first case involves the administration of phenytoin to an infant during a prolonged febrile seizure at a Scottish tertiary hospital. Despite the presence of a parent qualified as an American pediatric emergency physician—who advocated for the use of fosphenytoin to mitigate the risk of extravasation—the facility adhered to its internal protocol. This resulted in severe tissue necrosis requiring surgical intervention and prolonged wound management. The subsequent institutional review concluded that no error occurred because protocol was followed, illustrating a systemic prioritization of procedural adherence over clinical outcome. This suggests a culture where the absence of a protocol breach precludes the recognition of preventable harm, contrasting with the American model where regulatory and litigation pressures often necessitate a more rigorous, data-driven approach to error analysis.

第一個案例涉及在一家蘇格蘭三級醫院中，一名嬰兒在長時間發燒性抽搐期間被施用苯妥英鈉 (phenytoin)。儘管其中一名家長是美國合格的兒科急診醫師，且建議使用 fosphenytoin 以降低藥物外滲的風險，但該院仍堅持執行其內部方案。這導致了嚴重的組織壞死，需要手術干預及長期的傷口管理。隨後的機構審查結論認為，由於遵循了方案，因此並未發生錯誤，這說明了系統將程序的遵守置於臨床結果之上。這顯示出一種文化，即只要沒有違反方案，就排除對可預防傷害的承認，與美國模式形成對比，後者由於監管和訴訟壓力，通常需要一種更嚴謹、由數據驅動的錯誤分析方法。

Parallel systemic vulnerabilities are evidenced in a second incident involving a five-year-old patient. A physician associate (PA) prescribed a vaginal pessary for suspected thrush without the requisite prescribing authority or physician supervision. The pharmacy further failed to intercept this age-inappropriate prescription. The Parliamentary and Health Service Ombudsman (PHSO) identified these as critical failures, which not only caused physical injury but also led to unwarranted investigations into sexual abuse. This event underscores a failure in professional boundary enforcement and pharmaceutical oversight. Consequently, the Royal College of GPs has issued guidance suggesting that PAs should not manage patients under the age of 16, reflecting a shift toward more stringent clinical governance to prevent similar occurrences.

第二個案例則證明了平行的系統脆弱性，涉及一名五歲患者。一名醫師助理 (PA) 在缺乏必要處方權限或醫師監督的情況下，為一名疑似患有霉菌性陰道炎的患者開立了陰道栓劑處方。藥局進一步未能攔截此不符合年齡的處方。議會及醫療服務監察專員 (PHSO) 將其定義為關鍵失效，不僅造成身體傷害，還導致了不必要的性虐待調查。此事件凸顯了專業界限執法與藥局監督的失效。因此，英國全科醫師學院 (Royal College of GPs) 已發布指引，建議 PA 不應管理 16 歲以下的患者，反映出臨床治理正向更嚴格的方向轉移，以防止類似事件再次發生。

Current evidence indicates that adherence to formal protocols does not inherently guarantee patient safety and that gaps in professional oversight continue to pose risks to pediatric populations.

目前的證據表明，遵循正式方案並不必然保證病人安全，且專業監督的缺失繼續對兒科人群構成風險。